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Enzyme-coated Janus nanoparticles that
selectively bind cell receptors as a function of the
concentration of glucose†
Gabriele Rucinskaite,a Sebastian A. Thompson,a,b Sureyya Patersona and
Roberto de la Rica *a,c
A method is proposed for controlling the number of nanoparticles
bound to cell membranes via RGDS peptide–integrin interactions.
It consists of propelling nanoparticles bearing the peptides with
enzymes (glucose oxidase), which disrupts biomolecular inter-
actions as a function of the concentration of enzyme substrate
(glucose).
Biorecognition, that is, the ability of certain biomolecules to
specifically bind to a target molecule, is a fundamental
phenomenon in biology that underpins the outstanding com-
plexity of the cellular machinery. In vitro, biorecognition reac-
tions can be used to fabricate biosensors for the detection of a
wide array of analytes, from disease biomarkers and patho-
gens, to small molecules and environmental pollutants.1–3
In targeted drug delivery, medicines modified with bio-
recognition elements preferentially bind to cells overexpressing
a particular cell receptor. This increases the number of inter-
actions with the cells, which in turn increases the retention
time and cellular uptake.4,5 The selectivity of these biosensing
and drug delivery approaches could be enhanced even further
if biomolecular interactions could be disrupted as a function
of an external stimulus. For example, the signal-to-noise ratio
of a biosensor could be greatly improved if low-specificity
interactions could be disrupted on demand. In drug delivery,
medicines capable of unbinding healthy cells as a function of
an external stimulus could reduce unwanted side eﬀects
because they would accumulate less in healthy tissue.
In this manuscript we introduce a new method for disrupt-
ing biomolecular interactions as a function of the concen-
tration of glucose. This method consists of attaching bio-
molecules to Janus particles that are partially covered with
enzymes (Fig. 1a). It has been proposed that enzyme-coated
Janus nanoparticles can move by means of a diﬀusiophoretic
mechanism.6,7 The velocity of these Janus particles is related
to the concentration of the enzyme substrate. It is also well
established that biomolecular interactions can be mechani-
cally disrupted, for example, by pulling biomolecules apart
with an atomic force microscope or with optical tweezers.8
Here we propose that the mechanical force generated by the
motion of enzyme-coated Janus particles can also be used to
disrupt biomolecular interactions and unbind the nano-
particles from the cell membrane (Fig. 1b). To prove this
concept we prepared nanoparticles partially coated with
glucose oxidase (GOx) and a biomolecule that interacts with a
cell receptor (RGDS, a peptide that targets integrins,9–12
Fig. 1a). GOx increases the diﬀusion coeﬃcient of the nano-
particles,13,14 which decreases the number of nanoparticles
bound to cells as a function of the concentration of the
Fig. 1 Schematic representation of the proposed method for selectively
binding cell receptors. (a) Janus nanoparticles partially covered with
enzymes (glucose oxidase, GOx) establish RGDS–integrin interactions
with cell membranes. (b) The Janus particles move in the presence of
the enzyme substrate glucose (S); this generates a mechanical force that
disrupts biomolecular interactions (P is the product of the enzymatic
reaction).
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enzyme substrate. The particle design could be easily adapted
to respond to the concentration of other metabolites such
as urea or hydrogen peroxide by simply changing GOx for
urease or catalase, respectively.6,7 This concept is promising
for developing a new family of particles that selectively
establish interactions with cells as a function of the con-
centration of diﬀerent metabolites present in the cell
microenvironment.
The Janus structure consisting of two hemispheres with
diﬀerent chemical composition (Fig. 1a) enables an asym-
metric distribution of the products of the enzymatic reaction
around the colloids, which is a crucial factor to trigger the
diﬀusiophoretic mechanism responsible for the motion of
the particles.15 Fig. 2a depicts the method used here for
obtaining Janus particles that are partially covered with
enzymes and other biomolecules. Streptavidin-coated mag-
netic particles are the starting material for preparing Janus
particles. An asymmetric distribution of enzymes and bio-
molecules on the surface of these particles was obtained
with a variant of the well-known method of desymmetriza-
tion at interfaces.16 It involves holding the streptavidin-
coated colloids with a magnet (Fig. 2a(i)) while modifying
the surface exposed to the solvent with biotinylated enzymes
(Fig. 2a(ii)). After removing the magnet, Janus particles par-
tially covered with enzymes are obtained (Fig. 2a(iii)). The
free streptavidin binding sites can now be modified with
another biotinylated molecule, for example biotinylated
RGDS peptides (Fig. 2a(iv)). The procedure for obtaining
Janus particles was tested with micrometric magnetic par-
ticles, which enabled detecting the asymmetric coating with
optical microscopy. In Fig. 2b when the streptavidin-modi-
fied particles were coated with biotinylated fluorescent BSA
the Janus structure could be visualized with fluorescence
microscopy. In these images the darker areas contain non-
fluorescent GOx whereas the bright spots are modified with
fluorescent BSA (see also Fig. S2 in ESI†). In Fig. 2c, control
colloids that were not modified with fluorescent BSA show a
homogenous background fluorescence signal, which demon-
strates that the diﬀerences in fluorescence intensity observed
in Fig. 2b are originated by the asymmetric coating of the
particles with GOx and fluorescent BSA. Janus particles
based on magnetic iron oxide nanoparticles have been pre-
viously obtained with a variety of methods, including
seed-and-growth consecutive steps,17 a flame synthetic
approach,18 or the deposition of iron oxide on cores with
physical vapor deposition.19 The proposed method is particu-
larly advantageous for preparing Janus particles coated with
biomolecules because it avoids the utilization of harsh
etching,20 or sonication,21 steps that could denature the pro-
teins on the surface of the particles.
We then studied the motion of the GOx-modified nano-
particles as a function of the concentration of glucose. Janus
nanoparticles with a diameter of 220 ± 40 nm were prepared
following the method shown in Fig. 2. This size was chosen
because it is similar to the size of previously reported enzyme-
powered nanomotors.7,14 Nanoparticle motion was studied
with dynamic light scattering (DLS), which is a validated tech-
nique for studying changes in the diﬀusion coeﬃcient of
enzyme-covered Janus nanoparticles.7 The diﬀusion coeﬃcient
of the nanoparticles in the absence of glucose is 0.36 ±
0.01 μm2 s−1. This value is similar to the diﬀusion coeﬃcient
reported for hollow Janus silica particles decorated with GOx,
which have been previously proposed as enzyme-powered
nanomotors (0.72 μm2 s−1, diameter 389 nm).7 In Fig. 3 the
apparent diﬀusion coeﬃcient increases with the concentration
of glucose in the concentration range between 0 and 60 mM.
Fig. 2 Fabrication and characterization of Janus particles.
(a) Schematic representation of the method followed here for obtaining
GOx-covered Janus particles (b) ﬂuorescence microscopy (FM) image of
a Janus particle containing asymmetrically distributed GOx and ﬂuor-
escent BSA; (c) FM image of a Janus particle modiﬁed only with GOx.
Fig. 3 Variation of the diﬀusion coeﬃcient (D) of GOx-modiﬁed Janus
nanoparticles as a function of the concentration of the enzyme sub-
strate glucose (semi-logarithmic scale). Error bars are the standard devi-
ation of 3 independent experiments. The plotted line is a guide for the
eyes.
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The apparent diﬀusion coeﬃcient increased by 23% upon
addition of 60 mM glucose (from 0.36 ± 0.01 to 0.44 ±
0.05 μm2 s−1), which is similar to the 24% increase reported
for hollow mesoporous nanoparticles in the presence of
75 mM glucose.7 D values at 0 and 60 mM glucose are signifi-
cantly diﬀerent from each other (p < 0.05). Although the
experiments are rather noisy, the general trend observed in
Fig. 3 agrees well with the idea that the proposed Janus nano-
particles move in the presence of glucose in a concentration-
dependent manner, as previously demonstrated for other GOx-
decorated Janus nanoparticles.
Next we studied the impact of the glucose concentration in
the binding of the nanoparticles to integrins present in cell
membranes. Integrins are often overexpressed in tumors, and
drugs capable of targeting these proteins have been shown to
have a greater eﬀect on cancer cells.22 To study the interaction
between RGDS and integrins, CHO cells were first fixated with
4%, paraformaldehyde a method that has been previously uti-
lized in similar bioimaging studies.23,24 This procedure
allowed us to study the binding of nanoparticles to the plasma
membrane independently from cell uptake, since fixated cells
do not internalize nanoparticles. Furthermore adding glucose at
diﬀerent concentrations to live cells changes their behavior, cell
membrane composition and metabolic profile, making it
diﬃcult to study peptide–integrin interactions with confi-
dence.25,26 The proteins on the nanoparticles were modified
with fluorescein in order to visualize them easily with fluo-
rescence microscopy. Fig. 4a shows a representative fluo-
rescence microscopy image of the cells after incubation with
nanoparticles for 2 h (see also Fig. S3 in ESI†). In this image the
cells become fluorescent due to the specific binding of the
nanoparticles to the cell membrane, since nanoparticles that
were not modified with RGDS did not stain the cell membrane
(see Fig. S6 in ESI†). In Fig. 4b and c the same experiment was
performed but adding glucose to a final concentration of 1 mM
and 10 mM, respectively (see also Fig. S4 and S5 in ESI†). Under
these conditions the relative fluorescence intensity around the
cells decreases which indicates that less nanoparticles bind to
their membranes. In Fig. 4d the average fluorescence intensity
was calculated for each glucose concentration. In this figure the
fluorescence intensity decreases as the glucose concentration
increases. Fluorescence intensity values are significantly
diﬀerent from each other (p < 0.05). This means that less nano-
particles are attached to the cell membrane when the concen-
tration of enzyme substrate increases. These results are in agree-
ment with the hypothesis in Fig. 1 that nanoparticle motion
triggered by enzymes disrupts the binding between peptide-
coated nanoparticles and cell membranes.
Conclusions
In conclusion, we have demonstrated that it is possible to
control the number of GOx-coated Janus nanoparticles bound
to cells via peptide–integrin interactions by fine-tuning the
concentration of the enzyme substrate glucose. The key factor
to control the number of nanoparticles bound the cells is trig-
gering the diﬀusiophoretic motion of the colloids.
Controlling the number of nanoparticles bound to cell mem-
branes as a function of the concentration of metabolites
could be useful for designing medicines and bioimaging
probes that selectively target cells as a function of bio-
molecular cues in their microenvironment. For instance, the
concentration of glucose in healthy tissue is 10 mM. In the
tumor microenvironment this value is 3–10 lower due to the
accelerated metabolism of cancer cells.27 The results in Fig. 4
are promising for designing Janus nanoparticles decorated
with RGDS and GOx that selectively disrupt RGDS–integrin
interactions in healthy tissue, where the concentration of
glucose is higher. Drug delivery platforms using these nano-
particles would reduce unwanted side eﬀects in healthy
tissue. For example hollow mesoporous Janus nanomotors,
which have a high drug-loading capacity,7 could be used to
deliver drugs selectively to cancerous tissue. In the context of
cancer therapy, the magnetic particles proposed here could
be used to kill cancer cells with magnetothermal therapy with
reduced side eﬀects.28 Similarly bioimaging nanoprobes
based on this design (e.g. MRI probes based on the proposed
Janus magnetic nanoparticles)29 could reduce background
signals and improve the signal-to-noise ratio when imaging
glucose-deficient tumors.
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Fig. 4 Fluorescence microscopy images of ﬁxated cells after incubation
with ﬂuorescent Janus nanoparticles decorated with GOx and RGDS
peptides in the presence of glucose with a concentration of: (a) 0, (b) 1,
or (d) 10 mM. Scale bars: 100 μm. (d) Mean ﬂuorescence intensity of
individual cells as a function of the concentration of glucose; error bars
are the standard deviation (n = 100).
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